Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of BI 6727 in recurrent platinum-resistant or platinum-refractory ovarian cancer
2009-015770-35Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of volasertib in ovarian cancer (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Disease control rate at week 24. Started Feb 2010; status: completed.
02
Drugs
volasertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2009-015770-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015770-35.